ERYTECH announces second positive DSMB review of its Phase IIb study in Acute Myeloid Leukemia

ERYTECH announces that an independent Data and Safety Monitoring Board (DSMB) completed its second safety assessment of the company’s Phase IIb study in Acute Myeloid Leukemia (AML) and unanimously recommended continuation of the trial without modification.

Menu